Evangelos Kiskinis

Analysis Of Compounds For Pain And Sensory Disorders

Application

#2015030 Oct 22, 2015

Filed

Apr 21, 2015

Inventor

Adam Cohen (Cambridge, MA) · Joel Kralj (Somerville, MA) · Evangelos Kiskinis (Cambridge, MA)

Appl. No.

14/692214

Assignee

Q-STATE BIOSCIENCES, INC. (Cambridge, MA)

International Classification

G01N 33/50, G01N 33/68

Abstract

The invention generally relates to optical methods for characterizing the effects of compounds on pain and other sensory phenomena. The effect of compounds on pain and other sensory phenomena may be characterized using dorsal root ganglion (DRG) neurons or sensory neurons expressing optogenetic proteins that allow neural activity to be stimulated and detected optically. The invention provides cell-based optical assays for studying the molecular and cellular bases of pain and sensory phenomena and as platforms to screen and validate drugs, e.g., for pre-clinical trials.

Diagnostic Methods For Neural Disorders

Application

#2017011 Apr 27, 2017

Filed

Jan 4, 2017

Inventor

Adam Cohen (Cambridge, MA) · Joel Kralj (Somerville, MA) · Evangelos Kiskinis (Cambridge, MA)

Appl. No.

15/398130

Assignee

Adam Cohen (Cambridge, MA) · Joel Kralj (Somerville, MA) · Evangelos Kiskinis (Cambridge, MA)

International Classification

G01N 33/50, G01N 21/64, G01N 33/68, G01N 33/487, C12N 5/0793

Abstract

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease

Functional Genomics Assay For Characterizing Pluripotent Stem Cell Utility And Safety

Application

#2013029 Nov 7, 2013

Filed

Sep 16, 2011

Inventor

Kevin C. Eggan (Boston, MA) · Alexander Meissner (Cambridge, MA) · Christoph Bock (Vienna, AT) · Evangelos Kiskinis (Boston, MA) · Griet Annie Frans Verstappen (Moltsel, BE)

Appl. No.

13/822336

Assignee

PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA)

International Classification

C12N 15/10

U.S. Classification

506 9, 506 16

Abstract

The present invention generally relates set of reference data or “scorecard” for a pluripotent stem cell, and methods, systems and kits to generate a scorecard for predicting the functionality and suitability of a pluripotent stem cell line for a desired use. In some aspects, a method for generating a scorecard comprises using at least 2 stem cell assays selected from: epigenetic profiling, differentiation assay and gene expression assay to predict the functionality and suitability of a pluripotent stem cell line for a desired use. In some embodiments, the scorecard reference data can be compared with the pluripotent stem cells data to effectively and accurately predict the utility of the pluripotent stem cell for a given application, as well as any to identify specific characteristics of the pluripotent stem cell line to determine their suitability for downstream applications, such as for example, their suitability for therapeutic use, drug screening and toxicity assays, differentiation into a desired cell lineage, and the like.

Methods To Treat Neurodegenerative Diseases

Application

#2015019 Jul 9, 2015

Filed

Aug 6, 2013

Inventor

Evangelos Kiskinis (Boston, MA) · Kevin Eggan (Boston, MA)

Appl. No.

14/420245

Assignee

Children's Medical Center Corporation (Boston, MA)

International Classification

A61K 31/325, G01N 33/483, G01N 33/50, A61K 31/428

Abstract

The present invention is based on the discovery that motor neurons derived from patients with a neuro-degenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neurons derived from control healthy individuals. The present invention is also based on the discovery that the class of compounds known as “potassium channel openers” can be used to treat neurodegenerative diseases, including ALS, Parkinson's disease, Alzheimer's disease, epilepsy, and pain.

Diagnostic Methods For Neural Disorders

Application

#2016028 Sep 29, 2016

Filed

May 10, 2016

Inventor

Adam Cohen (Cambridge, MA) · Joel Kralj (Somerville, MA) · Evangelos Kiskinis (Cambridge, MA)

Appl. No.

15/151006

Assignee

Adam Cohen (Cambridge, MA) · Joel Kralj (Somerville, MA) · Evangelos Kiskinis (Cambridge, MA)

International Classification

G01N 33/487, G01N 33/68, G01N 21/64, G01N 33/50

Abstract

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease

Dynamics Within Supramolecuar Ikvav Matrices Enhance Functional Maturation Of Human Ipscs-Derived Neurons And Regeneration

Application

#2022021 Jul 7, 2022

Filed

Jan 24, 2020

Inventor

Kohei Sato (Yokohama, JP) · Juan Alberto Ortega Cano (Chicago, IL) · Evangelos Kiskinis (Chicago, IL) · Samuel I. Stupp (Chicago, IL)

Appl. No.

17/425757

Assignee

Kohei Sato (Yokohama, JP) · Juan Alberto Ortega Cano (Chicago, IL) · Evangelos Kiskinis (Chicago, IL) · Samuel I. Stupp (Chicago, IL)

International Classification

C07K 7/06, A61P 25/00, C12N 5/00, C12N 5/0793, A61K 35/30

Abstract

Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury.